140 related articles for article (PubMed ID: 18637141)
1. Budgetary impact of varenicline in smoking cessation in the United Kingdom.
Taylor DC; Chu P; Rosen VM; Baker CL; Thompson D
Value Health; 2009; 12(1):28-33. PubMed ID: 18637141
[TBL] [Abstract][Full Text] [Related]
2. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
4. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM; Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and safety of varenicline for smoking cessation].
Christalla P; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
[TBL] [Abstract][Full Text] [Related]
9. Association of out-of-pocket pharmacy costs with adherence to varenicline.
Suehs BT; Davis C; Galaznik A; Joshi AV; Zou KH; Patel NC
J Manag Care Spec Pharm; 2014 Jun; 20(6):592-600. PubMed ID: 24856597
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
12. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
Knight C; Howard P; Baker CL; Marton JP
Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
[TBL] [Abstract][Full Text] [Related]
14. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.
Jackson KC; Nahoopii R; Said Q; Dirani R; Brixner D
J Occup Environ Med; 2007 Apr; 49(4):453-60. PubMed ID: 17426529
[TBL] [Abstract][Full Text] [Related]
15. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims.
Zeng F; Chen CI; Mastey V; Zou KH; Harnett J; Patel BV
Clin Ther; 2011 Feb; 33(2):225-34. PubMed ID: 21497706
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
Mahmoudi M; Coleman CI; Sobieraj DM
Int J Clin Pract; 2012 Feb; 66(2):171-82. PubMed ID: 22257042
[TBL] [Abstract][Full Text] [Related]
18. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
Getsios D; Marton JP; Revankar N; Ward AJ; Willke RJ; Rublee D; Ishak KJ; Xenakis JG
Pharmacoeconomics; 2013 Sep; 31(9):767-80. PubMed ID: 23821436
[TBL] [Abstract][Full Text] [Related]
19. Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.
Coleman T; Agboola S; Leonardi-Bee J; Taylor M; McEwen A; McNeill A
Health Technol Assess; 2010 Oct; 14(49):1-152, iii-iv. PubMed ID: 21040645
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Howard P; Knight C; Boler A; Baker C
Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
